P
Philippe Beuzeboc
Researcher at Curie Institute
Publications - 187
Citations - 6801
Philippe Beuzeboc is an academic researcher from Curie Institute. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 39, co-authored 169 publications receiving 5877 citations. Previous affiliations of Philippe Beuzeboc include PSL Research University & Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis,Karim Fizazi,Florence Joly,Stéphane Oudard,Franck Priou,Benjamin Esterni,Igor Latorzeff,Remy Delva,Ivan Krakowski,Brigitte Laguerre,Frederic Rolland,Christine Theodore,Gael Deplanque,Jean Marc Ferrero,Damien Pouessel,Loic Mourey,Philippe Beuzeboc,Sylvie Zanetta,Muriel Habibian,Jean-François Berdah,Jérôme Dauba,Marjorie Baciuchka,Christian Platini,Claude Linassier,Jean Luc Labourey,Jean-Pascal Machiels,Claude El Kouri,Alain Ravaud,Etienne Suc,Jean-Christophe Eymard,Ali Hasbini,Guilhem Bousquet,Michel Soulié +32 more
TL;DR: Docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer, and the data monitoring committee recommended treatment with granulocyte colony-stimulating factor.
Journal ArticleDOI
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun +18 more
TL;DR: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
Journal ArticleDOI
Prevalence of Renal Insufficiency in Cancer Patients and Implications for Anticancer Drug Management The Renal Insufficiency and Anticancer Medications (IRMA) Study
Vincent Launay-Vacher,Stéphane Oudard,Nicolas Janus,Joseph Gligorov,X. Pourrat,Olivier Rixe,Jean-François Morère,Philippe Beuzeboc,Gilbert Deray +8 more
TL;DR: The results from this study of nearly 5000 patients demonstrated the high prevalence of renal impairment in a population of patients with solid tumors.
Journal ArticleDOI
International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
Manfred Kaufmann,Gunter von Minckwitz,Roy E. Smith,Vicente Valero,Luca Gianni,Wolfgang Eiermann,Anthony Howell,Serban-Dan Costa,Philippe Beuzeboc,Michael Untch,Jens Uwe Blohmer,Hans-Peter Sinn,Rolf Sittek,Rainer Souchon,A. H. Tulusan,Tanja Volm,Hans-Jörg Senn +16 more
TL;DR: A group of representatives from breast cancer clinical research groups in France, Germany, Italy, the United Kingdom, and the United States reviewed all available data on prospective randomized trials in this setting to address concern about the use of PST in routine practice.
Journal ArticleDOI
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gwenaelle Gravis,Jean-Marie Boher,Florence Joly,Michel Soulié,Laurence Albiges,Franck Priou,Igor Latorzeff,Remy Delva,Ivan Krakowski,Brigitte Laguerre,Frederic Rolland,Christine Theodore,Gael Deplanque,Jean-Marc Ferrero,Stéphane Culine,Loic Mourey,Philippe Beuzeboc,Muriel Habibian,Stéphane Oudard,Karim Fizazi +19 more
TL;DR: In this paper, the authors evaluated the effect of docetaxel (D) added to androgen-deprivation therapy (ADT) in patients with metastatic high-volume disease.